Switch theme
Sign up to access all valuation multiples
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
1997
105
LTM Revenue $11.7M
LTM EBITDA -$24.9M
$90.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Heidelberg Pharma has a last 12-month revenue of $11.7M and a last 12-month EBITDA of -$24.9M.
In the most recent fiscal year, Heidelberg Pharma achieved revenue of $10.6M and an EBITDA of -$20.1M.
Heidelberg Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Heidelberg Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $19.9M | $10.6M | XXX | XXX | XXX |
| Gross Profit | -$3.2M | $14.9M | XXX | XXX | XXX |
| Gross Margin | -16% | 140% | XXX | XXX | XXX |
| EBITDA | -$17.4M | -$20.1M | XXX | XXX | XXX |
| EBITDA Margin | -87% | -190% | XXX | XXX | XXX |
| Net Profit | -$28.1M | -$21.2M | XXX | XXX | XXX |
| Net Margin | -141% | -200% | XXX | XXX | XXX |
| Net Debt | $4.6M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Heidelberg Pharma's stock price is EUR 3 (or $3).
Heidelberg Pharma has current market cap of EUR 120M (or $129M), and EV of EUR 83.8M (or $90.0M).
See Heidelberg Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $90.0M | $129M | XXX | XXX | XXX | XXX | $-0.53 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Heidelberg Pharma has market cap of $129M and EV of $90.0M.
Heidelberg Pharma's trades at 7.7x LTM EV/Revenue multiple, and -3.6x LTM EBITDA.
Analysts estimate Heidelberg Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Heidelberg Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $90.0M | XXX | XXX | XXX |
| EV/Revenue | 8.6x | XXX | XXX | XXX |
| EV/EBITDA | -4.2x | XXX | XXX | XXX |
| P/E | -5.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHeidelberg Pharma's NTM/LTM revenue growth is 2%
Heidelberg Pharma's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Heidelberg Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Heidelberg Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Heidelberg Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -47% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -203% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -201% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 53% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 285% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 352% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Heidelberg Pharma acquired XXX companies to date.
Last acquisition by Heidelberg Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Heidelberg Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Heidelberg Pharma founded? | Heidelberg Pharma was founded in 1997. |
| Where is Heidelberg Pharma headquartered? | Heidelberg Pharma is headquartered in Germany. |
| How many employees does Heidelberg Pharma have? | As of today, Heidelberg Pharma has 105 employees. |
| Is Heidelberg Pharma publicy listed? | Yes, Heidelberg Pharma is a public company listed on ETR. |
| What is the stock symbol of Heidelberg Pharma? | Heidelberg Pharma trades under HPHA ticker. |
| When did Heidelberg Pharma go public? | Heidelberg Pharma went public in 2006. |
| Who are competitors of Heidelberg Pharma? | Similar companies to Heidelberg Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Heidelberg Pharma? | Heidelberg Pharma's current market cap is $129M |
| What is the current revenue of Heidelberg Pharma? | Heidelberg Pharma's last 12-month revenue is $11.7M. |
| What is the current EBITDA of Heidelberg Pharma? | Heidelberg Pharma's last 12-month EBITDA is -$24.9M. |
| What is the current EV/Revenue multiple of Heidelberg Pharma? | Current revenue multiple of Heidelberg Pharma is 7.7x. |
| What is the current EV/EBITDA multiple of Heidelberg Pharma? | Current EBITDA multiple of Heidelberg Pharma is -3.6x. |
| What is the current revenue growth of Heidelberg Pharma? | Heidelberg Pharma revenue growth between 2023 and 2024 was -47%. |
| Is Heidelberg Pharma profitable? | Yes, Heidelberg Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
